Literature DB >> 12134024

Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro.

Valérie Castet1, Chantal Fournier, Alexandre Soulier, Rozenn Brillet, Joliette Coste, Dominique Larrey, Daniel Dhumeaux, Patrick Maurel, Jean-Michel Pawlotsky.   

Abstract

Chronic hepatitis C is a common cause of liver disease, the complications of which include cirrhosis and hepatocellular carcinoma. Treatment of chronic hepatitis C is based on the use of alpha interferon (IFN-alpha). Recently, indirect evidence based on mathematical modeling of hepatitis C virus (HCV) dynamics during human IFN-alpha therapy suggested that the major initial effect of IFN-alpha is to block HCV virion production or release. Here, we used primary cultures of healthy, uninfected human hepatocytes to show that: (i) healthy human hepatocytes can be infected in vitro and support HCV genome replication, (ii) hepatocyte treatment with IFN-alpha results in expression of IFN-alpha-induced genes, and (iii) IFN-alpha inhibits HCV replication in infected human hepatocytes. These results show that IFN-alpha acts primarily through its nonspecific antiviral effects and suggest that primary cultures of human hepatocytes may provide a good model to study intrinsic HCV resistance to IFN-alpha.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12134024      PMCID: PMC155162          DOI: 10.1128/jvi.76.16.8189-8199.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Hepatitis C therapy in treatment-naïve patients.

Authors:  J McHutchison
Journal:  Am J Med       Date:  1999-12-27       Impact factor: 4.965

2.  Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

Authors:  A U Neumann; N P Lam; H Dahari; D R Gretch; T E Wiley; T J Layden; A S Perelson
Journal:  Science       Date:  1998-10-02       Impact factor: 47.728

Review 3.  The molecular virology of hepatitis C.

Authors:  M E Major; S M Feinstone
Journal:  Hepatology       Date:  1997-06       Impact factor: 17.425

Review 4.  Pathogenesis, natural history, treatment, and prevention of hepatitis C.

Authors:  T J Liang; B Rehermann; L B Seeff; J H Hoofnagle
Journal:  Ann Intern Med       Date:  2000-02-15       Impact factor: 25.391

Review 5.  Hepatitis C virus: kinetics and quasispecies evolution during anti-viral therapy.

Authors:  S Zeuzem
Journal:  Forum (Genova)       Date:  2000 Jan-Mar

6.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

Authors:  T Poynard; P Marcellin; S S Lee; C Niederau; G S Minuk; G Ideo; V Bain; J Heathcote; S Zeuzem; C Trepo; J Albrecht
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

7.  Detection of widespread hepatocyte infection in chronic hepatitis C.

Authors:  V Agnello; G Abel; G B Knight; E Muchmore
Journal:  Hepatology       Date:  1998-08       Impact factor: 17.425

8.  In vitro infection of adult normal human hepatocytes in primary culture by hepatitis C virus.

Authors:  C Fournier; C Sureau; J Coste; J Ducos; G Pageaux; D Larrey; J Domergue; P Maurel
Journal:  J Gen Virol       Date:  1998-10       Impact factor: 3.891

9.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

10.  Hepatitis C virus RNA polymerase and NS5A complex with a SNARE-like protein.

Authors:  H Tu; L Gao; S T Shi; D R Taylor; T Yang; A K Mircheff; Y Wen; A E Gorbalenya; S B Hwang; M M Lai
Journal:  Virology       Date:  1999-10-10       Impact factor: 3.616

View more
  29 in total

1.  Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication.

Authors:  Victor E Buckwold; Jiayi Wei; Michelle Wenzel-Mathers; Julie Russell
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

2.  Inhibition of the protein kinase PKR by the internal ribosome entry site of hepatitis C virus genomic RNA.

Authors:  Jashmin Vyas; Androulla Elia; Michael J Clemens
Journal:  RNA       Date:  2003-07       Impact factor: 4.942

3.  Therapeutic implications of hepatitis C virus resistance to antiviral drugs.

Authors:  Jean-Michel Pawlotsky
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

4.  Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain.

Authors:  Wenyu Lin; Sun Suk Kim; Elaine Yeung; Yoshitaka Kamegaya; Jason T Blackard; Kyung Ah Kim; Michael J Holtzman; Raymond T Chung
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

5.  Effect of interferon alpha2b plus ribavirin treatment on selected growth factors in respect to inflammation and fibrosis in chronic hepatitis C.

Authors:  Panasiuk Anatol; Flisiak Robert; Prokopowicz Danuta
Journal:  World J Gastroenterol       Date:  2005-03-28       Impact factor: 5.742

6.  Hepatitis C virus impairs TLR3 signaling and inhibits IFN-λ 1 expression in human hepatoma cell line.

Authors:  Yizhong Wang; Jieliang Li; Xu Wang; Li Ye; Yu Zhou; Rebecca M Thomas; Wenzhe Ho
Journal:  Innate Immun       Date:  2013-03-25       Impact factor: 2.680

Review 7.  New therapies for chronic hepatitis C virus infection.

Authors:  Anouk Dev; Keyur Patel; John G McHutchison
Journal:  Curr Gastroenterol Rep       Date:  2004-02

8.  CD81 is required for hepatitis C virus glycoprotein-mediated viral infection.

Authors:  Jie Zhang; Glenn Randall; Adrian Higginbottom; Peter Monk; Charles M Rice; Jane A McKeating
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

Review 9.  Human systems immunology: hypothesis-based modeling and unbiased data-driven approaches.

Authors:  Arnon Arazi; William F Pendergraft; Ruy M Ribeiro; Alan S Perelson; Nir Hacohen
Journal:  Semin Immunol       Date:  2013-01-29       Impact factor: 11.130

10.  CD56+ T cells inhibit hepatitis C virus replication in human hepatocytes.

Authors:  Li Ye; Xu Wang; Shihong Wang; Yanjian Wang; Li Song; Wei Hou; Lin Zhou; He Li; Wenzhe Ho
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.